These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 18281557)
21. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis. Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907 [TBL] [Abstract][Full Text] [Related]
22. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. Cary ZD; Willingham MC; Lyles DS J Virol; 2011 Jun; 85(12):5708-17. PubMed ID: 21450822 [TBL] [Abstract][Full Text] [Related]
23. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia. Betancourt D; Ramos JC; Barber GN J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177 [TBL] [Abstract][Full Text] [Related]
24. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Galivo F; Diaz RM; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile R Gene Ther; 2010 Feb; 17(2):158-70. PubMed ID: 20016540 [TBL] [Abstract][Full Text] [Related]
26. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. Paglino JC; van den Pol AN J Virol; 2011 Sep; 85(18):9346-58. PubMed ID: 21734048 [TBL] [Abstract][Full Text] [Related]
27. Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET. Garcia-Moure M; Gonzalez-Huarriz M; Labiano S; Guruceaga E; Bandres E; Zalacain M; Marrodan L; de Andrea C; Villalba M; Martinez-Velez N; Laspidea V; Puigdelloses M; Gallego Perez-Larraya J; Iñigo-Marco I; Stripecke R; Chan JA; Raabe EH; Kool M; Gomez-Manzano C; Fueyo J; Patiño-García A; Alonso MM Clin Cancer Res; 2021 Mar; 27(6):1807-1820. PubMed ID: 33376098 [TBL] [Abstract][Full Text] [Related]
28. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection. Le Boeuf F; Niknejad N; Wang J; Auer R; Weberpals JI; Bell JC; Dimitroulakos J Int J Cancer; 2012 Aug; 131(3):E204-15. PubMed ID: 22173567 [TBL] [Abstract][Full Text] [Related]
29. Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses. Udayakumar TS; Betancourt DM; Ahmad A; Tao W; Totiger TM; Patel M; Marples B; Barber G; Pollack A Mol Cancer Res; 2020 Aug; 18(8):1232-1243. PubMed ID: 32366674 [TBL] [Abstract][Full Text] [Related]
30. Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. Wollmann G; Rogulin V; Simon I; Rose JK; van den Pol AN J Virol; 2010 Feb; 84(3):1563-73. PubMed ID: 19906910 [TBL] [Abstract][Full Text] [Related]
31. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Alain T; Lun X; Martineau Y; Sean P; Pulendran B; Petroulakis E; Zemp FJ; Lemay CG; Roy D; Bell JC; Thomas G; Kozma SC; Forsyth PA; Costa-Mattioli M; Sonenberg N Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1576-81. PubMed ID: 20080710 [TBL] [Abstract][Full Text] [Related]
33. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment. Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Saloura V; Wang LC; Fridlender ZG; Sun J; Cheng G; Kapoor V; Sterman DH; Harty RN; Okumura A; Barber GN; Vile RG; Federspiel MJ; Russell SJ; Litzky L; Albelda SM Hum Gene Ther; 2010 Jan; 21(1):51-64. PubMed ID: 19715403 [TBL] [Abstract][Full Text] [Related]